352 related articles for article (PubMed ID: 21321566)
1. Implementing prognostic and predictive biomarkers in CRC clinical trials.
Van Schaeybroeck S; Allen WL; Turkington RC; Johnston PG
Nat Rev Clin Oncol; 2011 Feb; 8(4):222-32. PubMed ID: 21321566
[TBL] [Abstract][Full Text] [Related]
2. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
Petty RD; Samuel LM; Murray GI; MacDonald G; O'Kelly T; Loudon M; Binnie N; Aly E; McKinlay A; Wang W; Gilbert F; Semple S; Collie-Duguid ES
BMC Cancer; 2009 Dec; 9():434. PubMed ID: 20003335
[TBL] [Abstract][Full Text] [Related]
3. Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis.
Rahman MR; Islam T; Gov E; Turanli B; Gulfidan G; Shahjaman M; Banu NA; Mollah MNH; Arga KY; Moni MA
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30658502
[TBL] [Abstract][Full Text] [Related]
4. CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer.
Nguyen MN; Choi TG; Nguyen DT; Kim JH; Jo YH; Shahid M; Akter S; Aryal SN; Yoo JY; Ahn YJ; Cho KM; Lee JS; Choe W; Kang I; Ha J; Kim SS
Oncotarget; 2015 Oct; 6(31):31674-92. PubMed ID: 26397224
[TBL] [Abstract][Full Text] [Related]
5. Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer.
Wilkinson K; Ng W; Roberts TL; Becker TM; Lim SH; Chua W; Lee CS
J Clin Pathol; 2021 Oct; 74(10):625-634. PubMed ID: 33753562
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoproteomic characterisation of human colon and rectal cancer.
Frejno M; Zenezini Chiozzi R; Wilhelm M; Koch H; Zheng R; Klaeger S; Ruprecht B; Meng C; Kramer K; Jarzab A; Heinzlmeir S; Johnstone E; Domingo E; Kerr D; Jesinghaus M; Slotta-Huspenina J; Weichert W; Knapp S; Feller SM; Kuster B
Mol Syst Biol; 2017 Nov; 13(11):951. PubMed ID: 29101300
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
8. BRAF testing in advanced colorectal cancer: is it ready for prime time?
Phillips B; Kalady M; Kim R
Clin Adv Hematol Oncol; 2010 Jun; 8(6):437-44. PubMed ID: 20733556
[TBL] [Abstract][Full Text] [Related]
9. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
[TBL] [Abstract][Full Text] [Related]
10. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
11. Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients.
Perakis SO; Thomas JE; Pichler M
Adv Exp Med Biol; 2016; 937():183-204. PubMed ID: 27573901
[TBL] [Abstract][Full Text] [Related]
12. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
13. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Hatch AJ; Sibley AB; Starr MD; Brady JC; Jiang C; Jia J; Bowers DL; Pang H; Owzar K; Niedzwiecki D; Innocenti F; Venook AP; Hurwitz HI; Nixon AB;
Cancer Med; 2016 Sep; 5(9):2249-60. PubMed ID: 27465221
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.
Taieb J; Jung A; Sartore-Bianchi A; Peeters M; Seligmann J; Zaanan A; Burdon P; Montagut C; Laurent-Puig P
Drugs; 2019 Sep; 79(13):1375-1394. PubMed ID: 31347092
[TBL] [Abstract][Full Text] [Related]
15. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
16. Integrative Gene Expression Profiling Analysis to Investigate Potential Prognostic Biomarkers for Colorectal Cancer.
Liu X; Bing Z; Wu J; Zhang J; Zhou W; Ni M; Meng Z; Liu S; Tian J; Zhang X; Li Y; Jia S; Guo S
Med Sci Monit; 2020 Jan; 26():e918906. PubMed ID: 31893510
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice.
Maurel J; Postigo A
Curr Cancer Drug Targets; 2015; 15(8):703-15. PubMed ID: 26452385
[TBL] [Abstract][Full Text] [Related]
18. Role of genomic markers in colorectal cancer treatment.
Allen WL; Johnston PG
J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
[TBL] [Abstract][Full Text] [Related]
19. Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage II-III Colorectal Cancer.
Wang Z; Xing K; Zhang B; Zhang Y; Chai T; Geng J; Qin X; Zhang X; Xu C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293319
[TBL] [Abstract][Full Text] [Related]
20. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]